A Study to Evaluate the Effect of Multiple Doses of Isavuconazole on the Pharmacokinetics of Metformin
Information source: Astellas Pharma Inc
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Pharmacokinetics of Isavuconazole; Pharmacokinetics of Metformin; Healthy Subjects
Intervention: isavuconazole (Drug); metformin (Drug)
Phase: Phase 1
Status: Completed
Sponsored by: Astellas Pharma Global Development, Inc. Official(s) and/or principal investigator(s): Medical Director, Study Director, Affiliation: Astellas Pharma Global Development, Inc.
Summary
The purpose of this study is to assess the effect of multiple doses of isavuconazole on the
pharmacokinetics of a single dose of metformin. Safety and tolerability of isavuconazole
will be assessed alone and in combination with metformin.
Clinical Details
Official title: A Phase 1, Open-Label Study to Evaluate the Effect of Multiple Doses of Isavuconazole on the Pharmacokinetics of Metformin
Study design: Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label
Primary outcome: Pharmacokinetics (PK) of metformin in plasma: Area Under the Concentration-Time Curve (AUC) from the time of dosing to the last quantifiable concentration (AUClast)PK of metformin in plasma: AUC from the time of dosing to infinity (AUCinf) PK of metformin in plasma: Maximum Concentration (Cmax)
Secondary outcome: PK variable for isavuconazole in plasma: Trough Concentration (Ctrough)Composite of PK variables for isavuconazole in plasma: AUCtau, Cmax and tmax Composite of PK variables for metformin in plasma: t1/2, tmax, CL/F and Vz/F
Detailed description:
Subjects will check-in to the clinic on Day - 1 and remain confined through completion of the
study procedures on Day 10.
A follow-up telephone call will be made on Day 16 to check on health status.
Eligibility
Minimum age: 18 Years.
Maximum age: 55 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- The subject has a body weight of at least 45 kg and a body mass index of 18 to 32
kg/m2, inclusive.
- QTcF must be 360 to 430 msec for males and 370 to 450 msec for females
- Aspartate aminotransferase (AST), alanine aminotransferase (ALT) and serum creatinine
must not be above the normal range.
- Female subject is of non-childbearing potential or if of childbearing potential must
use highly effective birth control from Screening through 28 days after the end of
the study. Females must not be breastfeeding or donate ova from Screening through 20
days after the end of the study.
- Male subject must be using highly effective contraception from Screening through 90
days after final study drug administration. Male subject must not donate sperm
starting at Screening through 90 days after final study drug administration.
Exclusion Criteria:
- The subject has a history of unexplained syncope, cardiac arrest, unexplained cardiac
arrhythmia or torsade de pointes, structural heart disease, or family history of
either Short or Long QT syndrome (suggested by sudden death of a close relative at a
young age due to possible or probable cardiac causes).
- The subject has a positive result for hepatitis B surface antigen, hepatitis C
antibodies at Screening or is known to be positive for human immunodeficiency virus.
- The subject has a known or suspected allergy to any of the components of the trial
products or the azole class of compounds, or a history of multiple and/or severe
allergies to drugs or foods, or a history of severe anaphylactic reactions.
- The subject is a smoker (any use of tobacco or nicotine containing products) in the
last 6 months.
- The subject has had treatment with any prescribed or non-prescribed drugs in the 2
weeks prior to Day 1, with the exception of occasional use of acetaminophen up to 2
g/day.
- The subject has participated in any interventional clinical study or has received any
investigational drugs within 30 days or 5 half-lives, whichever is longer, prior to
Screening.
- The subject has participated in a prior study with isavuconazole.
- The subject has history of consuming more than 14 units of alcoholic beverages per
week within 6 months prior to screening or has a history of alcoholism or
drug/chemical/substance abuse within past 2 years prior to screening or the subject
tests positive at screening or Day - 1 for alcohol or drugs of abuse.
- The subject is an employee of the Astellas Group or vendors involved in the study.
Locations and Contacts
California Clinical Trials Medical Group, Glendale, California 91026, United States
Additional Information
Starting date: February 2013
Last updated: June 20, 2013
|